184 related articles for article (PubMed ID: 34635011)
1. High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma.
Ju G; Xu C; Zeng K; Zhou T; Zang L
Bioengineered; 2021 Dec; 12(1):8965-8979. PubMed ID: 34635011
[TBL] [Abstract][Full Text] [Related]
2. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.
Yang YC; Chien MH; Lai TC; Tung MC; Jan YH; Chang WM; Jung SM; Chen MH; Yeh CN; Hsiao M
J Biomed Sci; 2021 Apr; 28(1):29. PubMed ID: 33888099
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin 2 expression is associated with poor prognosis in breast cancer.
Yang J; Li S; Wang J; Liu G; Zhang C; Li X; Liu X
Pathol Res Pract; 2024 Jun; 258():155326. PubMed ID: 38754328
[TBL] [Abstract][Full Text] [Related]
4. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.
Ye H; Zhang N
Comput Math Methods Med; 2021; 2021():1498924. PubMed ID: 34868337
[TBL] [Abstract][Full Text] [Related]
7. Identification of long non‑coding RNA‑mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2‑ and triple negative breast cancer.
Du Z; Gao W; Sun J; Li Y; Sun Y; Chen T; Ge S; Guo W
Int J Mol Med; 2019 Sep; 44(3):1015-1025. PubMed ID: 31257479
[TBL] [Abstract][Full Text] [Related]
8. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
10. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.
Toda H; Seki N; Kurozumi S; Shinden Y; Yamada Y; Nohata N; Moriya S; Idichi T; Maemura K; Fujii T; Horiguchi J; Kijima Y; Natsugoe S
Mol Oncol; 2020 Feb; 14(2):426-446. PubMed ID: 31755218
[TBL] [Abstract][Full Text] [Related]
11. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
12. LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p.
Zhang S; Wang B; Xiao H; Dong J; Li Y; Zhu C; Jin Y; Li H; Cui M; Fan S
Thorac Cancer; 2020 Jul; 11(7):1801-1816. PubMed ID: 32374522
[TBL] [Abstract][Full Text] [Related]
13. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
15. The Valuable Role of ARMC1 in Invasive Breast Cancer as a Novel Biomarker.
Gan Y; Zhong F; Wang H; Li L
Biomed Res Int; 2022; 2022():1740295. PubMed ID: 35378785
[TBL] [Abstract][Full Text] [Related]
16. BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.
Cai P; Lu Z; Wu J; Qin X; Wang Z; Zhang Z; Zheng L; Zhao J
J Cell Biochem; 2020 Mar; 121(3):2643-2654. PubMed ID: 31692043
[TBL] [Abstract][Full Text] [Related]
17. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
18. Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
Yang Y; Li F; Luo X; Jia B; Zhao X; Liu B; Gao R; Yang L; Wei W; He J
DNA Cell Biol; 2019 Oct; 38(10):1088-1099. PubMed ID: 31424267
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
20. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
